Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-HR
2020-004393-22Phase 3Completed
- Sponsor
- LIB Therapeutics, LLC
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and cardiac morbidity comparing Lerodalcibep with Placebo (2 arms). Primary endpoints: Percent change from baseline in LDL-C at Week 52 and Percent change from baseline in LDL-C at the mean of Weeks 50 and 52. Started May 2021; status: completed.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiacardiac morbidity
Beyond the preview
Go deeper on 2020-004393-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004393-22.